About PredxBio

PredxBio develops AI tools that utilize unbiased spatial analytics to analyze whole slide image pathology samples, enabling the identification of novel cell types and biomarkers with over 90% confidence. This technology enhances patient stratification for clinical trials and improves the precision of companion diagnostics, ultimately personalizing therapeutic options for immunotherapy cancer patients.

```xml <problem> Traditional pathology analysis relies on manual review of whole slide images, which can be subjective and time-consuming. Identifying subtle cellular patterns and interactions within the tumor microenvironment is challenging, hindering the discovery of novel biomarkers and effective patient stratification for immunotherapy. </problem> <solution> PredxBio offers an AI-powered spatial analytics platform that analyzes whole slide images of pathology samples to identify novel cell types and biomarkers. By applying unbiased spatial analysis and explainable AI, the platform uncovers previously unseen relationships between cells and their functional states. This technology enables more precise patient stratification for clinical trials, facilitates the development of highly predictive companion diagnostics, and ultimately personalizes therapeutic options for immunotherapy cancer patients. The platform's data-driven approach accelerates drug discovery by identifying novel targets and biomarkers, while also optimizing clinical workflows through increased efficiency and accuracy. </solution> <features> - Unbiased spatial analytics to identify novel cell types, biomarkers, and targets - Explainable AI to provide insights into cellular interactions and functional states - Automated analysis of whole slide images, reducing manual review time - Patient stratification for clinical trials with high precision - Development of highly predictive companion diagnostics and prognostics - Personalized adjuvant therapy options based on individual patient profiles - Identification of sub-populations of patient response to immunotherapy with >90% confidence </features> <target_audience> The primary users are clinicians and researchers in drug discovery and clinical development, specifically those focused on immunotherapy for cancer patients. </target_audience> ```

What does PredxBio do?

Where is PredxBio located?

PredxBio is based in Pittsburgh, United States.

When was PredxBio founded?

PredxBio was founded in 2017.

How much funding has PredxBio raised?

PredxBio has raised 2600000.

Location

Pittsburgh, United States

Founded

2017

Funding

2600000

Employees

14 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

PredxBio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

predxbio.com 2K+

Crunchbase

Founded 2017 – Pittsburgh, United States

Funding

Estimated Funding

$2M+

Team (10+)

No team information available.

Company Description

Problem

Traditional pathology analysis relies on manual review of whole slide images, which can be subjective and time-consuming. Identifying subtle cellular patterns and interactions within the tumor microenvironment is challenging, hindering the discovery of novel biomarkers and effective patient stratification for immunotherapy.

Solution

PredxBio offers an AI-powered spatial analytics platform that analyzes whole slide images of pathology samples to identify novel cell types and biomarkers. By applying unbiased spatial analysis and explainable AI, the platform uncovers previously unseen relationships between cells and their functional states. This technology enables more precise patient stratification for clinical trials, facilitates the development of highly predictive companion diagnostics, and ultimately personalizes therapeutic options for immunotherapy cancer patients. The platform's data-driven approach accelerates drug discovery by identifying novel targets and biomarkers, while also optimizing clinical workflows through increased efficiency and accuracy.

Features

Unbiased spatial analytics to identify novel cell types, biomarkers, and targets

Explainable AI to provide insights into cellular interactions and functional states

Automated analysis of whole slide images, reducing manual review time

Patient stratification for clinical trials with high precision

Development of highly predictive companion diagnostics and prognostics

Personalized adjuvant therapy options based on individual patient profiles

Identification of sub-populations of patient response to immunotherapy with >90% confidence

Target Audience

The primary users are clinicians and researchers in drug discovery and clinical development, specifically those focused on immunotherapy for cancer patients.